Hospital
Poplar Bluff Regional Medical Center LLC
Poplar Bluff Regional Medical Center LLC was paid $71.58M by Medicaid between Jan 2018 and Dec 2024, across 244 billing codes. Its largest line is Y7506, — 15% of everything it billed.
33Billing provider infoPOPLAR BLUFF REGIONAL MEDICAL CENTER LLC
POPLAR BLUFF, MO 63901
POPLAR BLUFF, MO 63901
33aNPI1700831724assigned 05/24/2006
33bProvider typePsychiatric Hospital Unit
28Total paid$71.58M
24GClaims850,270
24DCodes billed244
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Psychiatric Hospital Unit providers in Missouri
Rank by total paid#1 of 9
Median peer was paid$8.82M
This provider vs. median8.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official LALOR, PAULA controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 125,318 | $18.35M | |
| 2019 | 118,396 | $17.62M | |
| 2020 | 108,928 | $11.45M | |
| 2021 | 118,508 | $3.44M | |
| 2022 | 135,464 | $6.68M | |
| 2023 | 143,085 | $7.81M | |
| 2024incomplete | 100,571 | $6.23M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| Y7506 | 15% | 21,146 | 16,313 | $10.91M | |
| X4011 | State-specific procedure code | 10% | 29,970 | 25,491 | $7.16M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 8.7% | 36,372 | 33,212 | $6.25M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 6.5% | 34,239 | 32,101 | $4.68M |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 5.9% | 91,445 | 77,846 | $4.21M |
| X4006 | 5.4% | 4,587 | 2,986 | $3.89M | |
| 80053 | Comprehensive metabolic panel | 3.9% | 79,552 | 65,657 | $2.81M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.6% | 10,970 | 9,689 | $2.55M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 2.1% | 5,166 | 4,541 | $1.48M |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.9% | 24,257 | 20,269 | $1.37M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.7% | 12,257 | 11,094 | $1.24M |
| G0378 | Hospital observation service, per hour | 1.7% | 1,922 | 1,441 | $1.19M |
232 more codes
| D7999 | 1.6% | 387 | $1.14M | |
| 71045 | Radiologic examination, chest; single view | 1.6% | 25,252 | $1.13M |
| 81001 | 1.6% | 24,229 | $1.11M | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1.5% | 24,944 | $1.10M |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 1.5% | 2,667 | $1.08M |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 1.4% | 8,473 | $995K |
| 43249 | 1.3% | 1,750 | $959K | |
| 81025 | 1.3% | 5,808 | $912K | |
| 36415 | Collection of venous blood by venipuncture | 1.2% | 30,947 | $892K |
| Y7507 | 1.1% | 2,186 | $761K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 1.1% | 12,146 | $754K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 3,485 | $612K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 6,067 | $581K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 3,005 | $533K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 1,395 | $510K |
| 80306 | <1% | 9,282 | $509K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 7,952 | $455K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 7,043 | $447K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 4,497 | $413K |
| 86140 | <1% | 12,676 | $392K | |
| 87430 | <1% | 6,682 | $383K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 20,646 | $348K |
| X4003 | <1% | 1,235 | $314K | |
| D2930 | Prefabricated stainless steel crown - primary tooth | <1% | 537 | $297K |
| 83735 | <1% | 17,872 | $293K | |
| 81003 | <1% | 15,171 | $281K | |
| 87040 | <1% | 5,139 | $279K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 3,910 | $265K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 6,846 | $257K |
| 86756 | <1% | 1,898 | $239K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,313 | $232K |
| 85610 | <1% | 12,555 | $226K | |
| 84484 | <1% | 13,296 | $217K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 5,378 | $211K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 4,526 | $208K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 2,819 | $194K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,500 | $188K |
| 83690 | <1% | 9,682 | $187K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 3,151 | $182K |
| 94664 | <1% | 863 | $170K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,397 | $168K |
| 85730 | <1% | 8,188 | $155K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 10,025 | $151K |
| 82962 | <1% | 7,595 | $147K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 2,455 | $137K |
| 83880 | <1% | 6,047 | $130K | |
| 82550 | <1% | 2,373 | $115K | |
| 84439 | <1% | 2,320 | $114K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 13,323 | $114K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,062 | $89K |
| 83605 | <1% | 6,868 | $84K | |
| J3490 | Unclassified drugs | <1% | 25,094 | $79K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 985 | $74K |
| 87076 | <1% | 192 | $71K | |
| 00170 | Anesthesia for intraoral procedures, including biopsy | <1% | 29 | $70K |
| 71250 | <1% | 1,888 | $69K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 565 | $66K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 537 | $64K |
| 84702 | <1% | 653 | $60K | |
| 11043 | <1% | 429 | $60K | |
| 87807 | <1% | 4,545 | $59K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 29 | $58K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 741 | $56K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 799 | $56K |
| 73562 | <1% | 1,814 | $52K | |
| 99156 | <1% | 1,105 | $47K | |
| 87186 | <1% | 2,395 | $45K | |
| 99157 | <1% | 1,079 | $43K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 73 | $42K |
| 82553 | <1% | 1,098 | $42K | |
| 82150 | <1% | 2,685 | $42K | |
| D7140 | Extraction, erupted tooth or exposed root | <1% | 173 | $41K |
| 94726 | <1% | 437 | $41K | |
| 0000000 | <1% | 672 | $38K | |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 317 | $33K |
| 82784 | <1% | 2,148 | $33K | |
| 83516 | <1% | 1,361 | $33K | |
| 87077 | <1% | 1,360 | $33K | |
| 80061 | Lipid panel | <1% | 2,769 | $29K |
| 81000 | <1% | 3,557 | $28K | |
| 17250 | <1% | 411 | $26K | |
| 87428 | <1% | 425 | $24K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 39 | $24K |
| 87081 | <1% | 3,321 | $24K | |
| 58558 | <1% | 18 | $23K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,657 | $21K |
| 95819 | <1% | 70 | $21K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 66 | $20K |
| 91110 | <1% | 32 | $19K | |
| 73110 | <1% | 470 | $19K | |
| 94010 | <1% | 279 | $18K | |
| 85651 | <1% | 1,644 | $18K | |
| D2390 | <1% | 46 | $17K | |
| 88312 | <1% | 535 | $16K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 188 | $16K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 442 | $16K |
| 84145 | <1% | 1,490 | $15K | |
| 94060 | <1% | 115 | $14K | |
| 86803 | <1% | 204 | $14K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 444 | $14K |
| 83655 | <1% | 1,244 | $13K | |
| 94729 | <1% | 355 | $13K | |
| 72114 | <1% | 219 | $13K | |
| 59409 | Vaginal delivery only (with or without episiotomy and/or forceps) | <1% | 25 | $13K |
| 85379 | <1% | 710 | $12K | |
| 82077 | <1% | 1,239 | $12K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 218 | $11K |
| 86787 | <1% | 174 | $11K | |
| 62323 | <1% | 46 | $10K | |
| 72110 | <1% | 131 | $9K | |
| 88304 | <1% | 192 | $9K | |
| 73030 | <1% | 401 | $8K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 186 | $8K |
| 74018 | <1% | 104 | $8K | |
| 87280 | <1% | 539 | $7K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 28 | $7K |
| 87641 | <1% | 246 | $7K | |
| 86364 | <1% | 844 | $7K | |
| 76830 | Ultrasound, transvaginal | <1% | 73 | $6K |
| 84703 | <1% | 278 | $6K | |
| 82248 | <1% | 210 | $6K | |
| 82247 | <1% | 209 | $6K | |
| 99460 | <1% | 88 | $6K | |
| 87581 | <1% | 163 | $5K | |
| 87486 | <1% | 163 | $5K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 68 | $5K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 71 | $5K |
| 82105 | <1% | 407 | $5K | |
| 81596 | <1% | 85 | $5K | |
| 77336 | <1% | 101 | $4K | |
| 80305 | <1% | 483 | $4K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 338 | $4K |
| 84100 | <1% | 249 | $4K | |
| 11045 | <1% | 701 | $4K | |
| 80081 | <1% | 29 | $4K | |
| 78226 | <1% | 12 | $4K | |
| 83550 | <1% | 412 | $3K | |
| 87070 | <1% | 1,146 | $3K | |
| 83540 | <1% | 546 | $3K | |
| 82728 | <1% | 354 | $3K | |
| 00813 | <1% | 468 | $3K | |
| 97597 | <1% | 67 | $3K | |
| 80074 | <1% | 70 | $3K | |
| 78264 | <1% | 14 | $3K | |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 51 | $2K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 184 | $2K |
| 82803 | <1% | 171 | $2K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,170 | $2K |
| 73502 | <1% | 71 | $2K | |
| 73130 | <1% | 79 | $2K | |
| 87205 | <1% | 1,201 | $2K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 16 | $2K |
| 82607 | <1% | 205 | $2K | |
| 82746 | <1% | 203 | $2K | |
| 86235 | <1% | 98 | $2K | |
| 73610 | <1% | 65 | $2K | |
| 96417 | <1% | 257 | $2K | |
| 96523 | <1% | 60 | $1K | |
| 72141 | <1% | 18 | $1K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 522 | $1K |
| 20610 | <1% | 19 | $1K | |
| 93923 | <1% | 38 | $1K | |
| 70486 | <1% | 12 | $1K | |
| 82378 | <1% | 149 | $1K | |
| 86003 | <1% | 165 | $1K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 41 | $950.55 |
| 81002 | <1% | 268 | $932.10 | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 18 | $859.92 |
| 82950 | <1% | 55 | $845.15 | |
| 72131 | <1% | 13 | $845.08 | |
| 72052 | <1% | 12 | $756.84 | |
| 87075 | <1% | 231 | $752.39 | |
| 82104 | <1% | 57 | $598.10 | |
| 86255 | <1% | 71 | $546.87 | |
| 86008 | <1% | 35 | $539.28 | |
| 86038 | <1% | 71 | $535.12 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,076 | $527.13 |
| 84466 | <1% | 57 | $519.44 | |
| 87522 | Neg quan hep c or qual rna | <1% | 13 | $505.90 |
| 87400 | <1% | 15 | $467.07 | |
| 72100 | <1% | 35 | $458.31 | |
| 36591 | <1% | 156 | $453.90 | |
| 82390 | <1% | 57 | $444.54 | |
| 96415 | <1% | 25 | $420.54 | |
| 36600 | <1% | 98 | $370.19 | |
| 85018 | <1% | 28 | $364.97 | |
| 85014 | <1% | 28 | $364.97 | |
| C1726 | Catheter, balloon dilatation, non-vascular | <1% | 403 | $266.43 |
| 84134 | <1% | 77 | $242.93 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,205 | $205.92 |
| 86225 | <1% | 25 | $204.69 | |
| 85044 | <1% | 13 | $157.42 | |
| 73630 | <1% | 14 | $148.07 | |
| 86161 | <1% | 12 | $144.48 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 189 | $143.39 |
| 85027 | <1% | 42 | $139.18 | |
| 80143 | <1% | 12 | $133.07 | |
| 80179 | <1% | 12 | $133.07 | |
| 99152 | <1% | 342 | $132.09 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 534 | $131.68 |
| 84133 | <1% | 13 | $84.00 | |
| 85652 | <1% | 56 | $79.81 | |
| 20552 | <1% | 20 | $68.94 | |
| 80069 | <1% | 15 | $62.15 | |
| 80076 | <1% | 17 | $60.70 | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 14 | $47.20 |
| 86901 | <1% | 13 | $43.85 | |
| 99153 | Mod sedat endo service >5yrs | <1% | 62 | $36.16 |
| 83615 | <1% | 13 | $26.09 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 174 | $11.84 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 85 | $6.36 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 60 | $5.44 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 12 | $0.42 |
| J2704 | Injection, propofol, 10 mg | 0% | 2,937 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 350 | $0.00 |
| 96377 | 0% | 77 | $0.00 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 494 | $0.00 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 2,438 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 270 | $0.00 |
| C1889 | Implantable/insertable device, not otherwise classified | 0% | 198 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 350 | $0.00 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 0% | 14 | $0.00 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 0% | 18 | $0.00 |
| 80050 | General health panel | 0% | 18 | $0.00 |
| J1020 | Injection, methylprednisolone acetate, 20 mg | 0% | 285 | $0.00 |
| G1002 | Clinical decision support mechanism medcurrent, as defined by the medicare appropriate use criteria program | 0% | 76 | $0.00 |
| 00731 | 0% | 66 | $0.00 | |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 32 | $0.00 |
| J2916 | Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | 0% | 25 | $0.00 |
| 81401 | 0% | 19 | $0.00 | |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 18 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 60 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLALOR, PAULA (DIRECTOR/DELEGATED OFFICIAL)
| Provider | Location | Paid |
|---|---|---|
| Roswell Hospital Corporation | Roswell, NM | $41.27M |
| Wesley Health System LLC | Hattiesburg, MS | $37.82M |
| Metro Knoxville Hma LLC | Powell, TN | $28.70M |
| Bullhead City Hospital Corporation | Bullhead City, AZ | $28.54M |
| Iom Health System LP | Fort Wayne, IN | $27.50M |
| ST. Joseph Health System, LLC | Fort Wayne, IN | $25.43M |
| Laredo Texas Hospital Company LP | Laredo, TX | $19.46M |
| Oak Hill Hospital Corporation | Oak Hill, WV | $18.77M |
| Cocke County Hma, LLC | Newport, TN | $18.34M |
| Cleveland Tennessee Hospital Company LLC | Cleveland, TN | $16.31M |
| Jefferson County Hma LLC | Jefferson City, TN | $14.31M |
| Northwest Arkansas Hospitals, LLC | Springdale, AR | $11.46M |
| Petersburg Hospital Company LLC | Petersburg, VA | $11.20M |
| Campbell County Hma, LLC | Lafollette, TN | $10.07M |
| Warsaw Health System LLC | Warsaw, IN | $9.95M |
| Longview Medical Center LP | Longview, TX | $9.29M |
| Moberly Hospital Company LLC | Moberly, MO | $8.61M |
| Crestview Hospital Company, LLC | Crestview, FL | $8.15M |
| Kirksville Missouri Hospital Company, LLC | Kirksville, MO | $7.98M |
| Victoria of Texas LP | Victoria, TX | $7.74M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.